These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9263613)

  • 1. Efficacy of ipriflavone in established osteoporosis and long-term safety.
    Agnusdei D; Bufalino L
    Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
    Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
    Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
    Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
    JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design for an ipriflavone multicenter European fracture study.
    Reginster JY; Bufalino L; Christiansen C; Devogelaer JP; Gennari C; Riis BJ; Roux C
    Calcif Tissue Int; 1997; 61 Suppl 1():S28-32. PubMed ID: 9263614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
    Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
    Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
    Agnusdei D; Adami S; Cervetti R; Crepaldi G; Di Munno O; Fantasia L; Isaia GC; Letizia G; Ortolani S; Passeri M
    Bone Miner; 1992 Oct; 19 Suppl 1():S43-8. PubMed ID: 1422320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
    Kovács AB
    Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
    Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
    Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
    Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
    Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
    Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
    Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
    Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
    Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ipriflavone on bone mass in elderly osteoporotic women.
    Passeri M; Biondi M; Costi D; Bufalino L; Castiglione GN; Di Peppe C; Abate G
    Bone Miner; 1992 Oct; 19 Suppl 1():S57-62. PubMed ID: 1422322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
    Agnusdei D; Gennari C; Bufalino L
    Osteoporos Int; 1995; 5(6):462-6. PubMed ID: 8695969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
    Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
    Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.